up-to-date with a click!
Update January, 2018
 
Curated by Peter Lansberg,
a Dutch lipidologist and educator, and
reviewed by prof. Philip Barter, Past President of the
International Atherosclerosis Society.
The IAS Statin Newsletter will keep you up-to-date with all recent statin publications, using a curated approach to select relevant articles.

Statin publications January 2018

Other

  1. Sarpong EM, Zuvekas SH. Trends in Statin Therapy among Adults (Age >/= 18), United States, 2000 to 2011. In: Statistical Brief (Medical Expenditure Panel Survey (US)). Rockville (MD): Agency for Healthcare Research and Quality (US); 2001.
  2. Demasi MP. Statin wars: have we been misled about the evidence? A narrative review. British journal of sports medicine 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29353811
  3. Loukovaara S, Sahanne S, Takala A, Haukka J. Statin use and vitreoretinal surgery: Findings from a Finnish population-based cohort study. Acta ophthalmologica 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29338115
  4. Masjuan J, Gallego J, Aguilera JM et al. Use of cardiovascular polypills for the secondary prevention of cerebrovascular disease. Neurologia 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29325730
  5. Schiele F, Kristensen SD. The anti-statin lobby strikes again: time to set the record straight. Eur Heart J 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29300911

Add on treatments

  1. Uzokov J, Alyavi A, Alyavi B. Influence of combination therapy of rosuvastatin and telmisartan on vascular and metabolic profile in hypercholesterolemic patients with metabolic syndrome. Atherosclerosis 2017; 263:e241. http://www.ncbi.nlm.nih.gov/pubmed/?term=29365928
  2. Toth PP, Bays H, Farnier M et al. A comparison of the attainment of guideline-recommended LDL-C lowering with statin and ezetimibe+statin therapies. Atherosclerosis 2017; 263:e240-e241. http://www.ncbi.nlm.nih.gov/pubmed/?term=29365924
  3. Susekov A, Meshkov A, Scherbakova M. Fast regression of xanthomatosis in patient with homogous FH after intensive therapy with statin, ezetimibe and PCSK9 inhibitor evalocumab- the case. Atherosclerosis 2017; 263:e229-e230. http://www.ncbi.nlm.nih.gov/pubmed/?term=29365883
  4. Salami JA, Warraich HJ, Valero-Elizondo J et al. National Trends in Nonstatin Use and Expenditures Among the US Adult Population From 2002 to 2013: Insights From Medical Expenditure Panel Survey. J Am Heart Assoc 2018; 7. http://www.ncbi.nlm.nih.gov/pubmed/?term=29358195
  5. Greve AM, Bang CN, Boman K et al. Effect Modifications of Lipid-Lowering Therapy on Progression of Aortic Stenosis (from the Simvastatin and Ezetimibe in Aortic Stenosis [SEAS] Study). Am J Cardiol 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29361285
  6. Sun S, Wang R, Fan J et al. Effects of Danshen tablets on pharmacokinetics of atorvastatin calcium in rats and its potential mechanism. Pharmaceutical biology 2018; 56:104-108. http://www.ncbi.nlm.nih.gov/pubmed/?term=29322864
  7. Masjuan J, Gallego J, Aguilera JM et al. Use of cardiovascular polypills for the secondary prevention of cerebrovascular disease. Neurologia 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29325730
  8. Chen IC, Tseng WK, Li YH et al. Effect of cilostazol on plasma levels of proprotein convertase subtilisin/kexin type 9. Oncotarget 2017; 8:108042-108053. http://www.ncbi.nlm.nih.gov/pubmed/?term=29296222

Adherence

  1. Ofori-Asenso R, Jakhu A, Curtis AJ et al. A Systematic Review and Meta-analysis of the Factors Associated With Nonadherence and Discontinuation of Statins Among People Aged >/=65 Years. J Gerontol A Biol Sci Med Sci 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29360935
  2. Karlson BW, Jornten-Karlsson M, Xu Y et al. Rationale, design, and baseline characteristics of a randomised trial evaluating the effect of a smart phone based patient support tool on treatment duration in patients prescribed rosuvastatin in china (EHELP China). Atherosclerosis 2017; 263:e247-e248. http://www.ncbi.nlm.nih.gov/pubmed/?term=29365946
  3. Martin-Ruiz E, Olry-de-Labry-Lima A, Ocana-Riola R, Epstein D. Systematic Review of the Effect of Adherence to Statin Treatment on Critical Cardiovascular Events and Mortality in Primary Prevention. Journal of cardiovascular pharmacology and therapeutics 2018:1074248417745357. http://www.ncbi.nlm.nih.gov/pubmed/?term=29343082
  4. Alfian SD, Worawutputtapong P, Schuiling-Veninga CC et al. Pharmacy-based predictors of non-persistence and non-adherence to statin treatment among patients on oral diabetes medication in the Netherlands. Current medical research and opinion 2018:1-17. http://www.ncbi.nlm.nih.gov/pubmed/?term=29292657

Atherosclerosis & Imaging

  1. Pechlivanis S, Moebus S, Lehmann N et al. Pharmacogenetic association of blood-lipid related genetic variants with 5-year progression of coronary artery calcification following the treatment with statin in the Heinz Nixdorf Recall study. Atherosclerosis 2017; 263:e278. http://www.ncbi.nlm.nih.gov/pubmed/?term=29366052
  2. Nizomov A, Kenjaev S. Effect of high-dose atorvastatin on lipid spectrum and inflammation in acute myocardial infarction. Atherosclerosis 2017; 263:e245-e246. http://www.ncbi.nlm.nih.gov/pubmed/?term=29365940
  3. Mehrad H, Mokhtari-Dizaji M, Ghanaati H. Effect of high-dose atorvastatin therapy accompanied by discontinuation of cholesterol-rich diet on color-doppler ultrasonography parameters of atherosclerotic carotid artery. Atherosclerosis 2017; 263:e246. http://www.ncbi.nlm.nih.gov/pubmed/?term=29365942
  4. Matsuo N, Takaishi A, Oonishi N et al. EPA/AA can be a predictive factor in the patients with coronary artery disease in the strong statin era. Atherosclerosis 2017; 263:e196-e197. http://www.ncbi.nlm.nih.gov/pubmed/?term=29365757
  5. Luginova Z, Tripoten M, Pogorelova O et al. Effect of short-term intensive rosuvastatin therapy on carotid plaque volume in very high cardiovascular risk patients: A three-dimensional ultrasound imaging study. Atherosclerosis 2017; 263:e40-e41. http://www.ncbi.nlm.nih.gov/pubmed/?term=29366103
  6. Kozlov S, Kchamchieva L, Tripoten M et al. Effect of intensive statin therapy on carotid plaque echogenicity in patients with nonobstructive asymptomatic carotid stenosis. Atherosclerosis 2017; 263:e147. http://www.ncbi.nlm.nih.gov/pubmed/?term=29365582
  7. Greve AM, Bang CN, Boman K et al. Effect Modifications of Lipid-Lowering Therapy on Progression of Aortic Stenosis (from the Simvastatin and Ezetimibe in Aortic Stenosis [SEAS] Study). Am J Cardiol 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29361285
  8. Budoff M, Brent Muhlestein J, Le VT et al. Effect of Vascepa (icosapent ethyl) on progression of coronary atherosclerosis in patients with elevated triglycerides (200-499 mg/dL) on statin therapy: Rationale and design of the EVAPORATE study. Clin Cardiol 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29365351
  9. Afolabi A, Mustafina I, Zhao L et al. Does spotty calcification attenuate the response of nonculprit plaque to statin therapy?: A serial optical coherence tomography study. Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29359491
  10. Seo YH, Seo DJ, Song IG et al. Rationale of decreasing low-density lipoprotein cholesterol below 70 mg/dL in patients with coronary artery disease: A retrospective virtual histology. Intravascular ultrasound study. Cardiology journal 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29341060
  11. Ozbicer S, Gur M, Kalkan G et al. Chronic statin treatment is a predictor of pre-interventional infarct related artery patency in patients with ST elevation myocardial infarction treated with percutaneous coronary intervention. Kardiol Pol 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29350388
  12. Kang J, Kim YC, Park JJ et al. Increased epicardial adipose tissue thickness is a predictor of new-onset diabetes mellitus in patients with coronary artery disease treated with high-intensity statins. Cardiovascular diabetology 2018; 17:10. http://www.ncbi.nlm.nih.gov/pubmed/?term=29325562

Atorvastatin/Rosuvastatin

  1. Zhu B, Tang C. Atorvastatin upregulates expression of p16 and inhibits proliferation and migration of VSMCS via altered dna methylation. Atherosclerosis 2017; 263:e132. http://www.ncbi.nlm.nih.gov/pubmed/?term=29365530
  2. Yasuda H, Fujiwara A, Komiya S, Haze T. Effects of rosuvastatin add-on treatment on hyperlipidemia in type 2 diabetic patients with chronic kidney disease receiving ethyl icosapentate. Atherosclerosis 2017; 263:e241-e242. http://www.ncbi.nlm.nih.gov/pubmed/?term=29365927
  3. Wang WT, Hellkamp A, Doll JA et al. Lipid Testing and Statin Dosing After Acute Myocardial Infarction. J Am Heart Assoc 2018; 7. http://www.ncbi.nlm.nih.gov/pubmed/?term=29371200
  4. Uzokov J, Alyavi A, Alyavi B. Influence of combination therapy of rosuvastatin and telmisartan on vascular and metabolic profile in hypercholesterolemic patients with metabolic syndrome. Atherosclerosis 2017; 263:e241. http://www.ncbi.nlm.nih.gov/pubmed/?term=29365928
  5. Shahrezaee M, Oryan A, Bastami F et al. Comparative impact of systemic delivery of atorvastatin, simvastatin, and lovastatin on bone mineral density of the ovariectomized rats. Endocrine 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29372484
  6. Ong KL, Waters DD, Fayyad R et al. Relationship of High-Density Lipoprotein Cholesterol With Renal Function in Patients Treated With Atorvastatin. J Am Heart Assoc 2018; 7. http://www.ncbi.nlm.nih.gov/pubmed/?term=29358194
  7. Nizomov A, Kenjaev S. Effect of high-dose atorvastatin on lipid spectrum and inflammation in acute myocardial infarction. Atherosclerosis 2017; 263:e245-e246. http://www.ncbi.nlm.nih.gov/pubmed/?term=29365940
  8. Nikolic T, Zivkovic V, Jeremic N et al. Impact of atorvastatin and simvastatin on lipid and non-lipid biochemical risk factors in diet-induced hyperhomocisteinemia in wistar albino rats: A comparative study. Atherosclerosis 2017; 263:e136. http://www.ncbi.nlm.nih.gov/pubmed/?term=29365545
  9. Mehrad H, Mokhtari-Dizaji M, Ghanaati H. Effect of high-dose atorvastatin therapy accompanied by discontinuation of cholesterol-rich diet on color-doppler ultrasonography parameters of atherosclerotic carotid artery. Atherosclerosis 2017; 263:e246. http://www.ncbi.nlm.nih.gov/pubmed/?term=29365942
  10. Mehrad H, Farhoudi M, Foletti A. Confocal dual- pulse electrohydraulic shock wave therapy for advanced atherosclerosis regression accompanied by atorvastatin- loaded microbubbles administration. Atherosclerosis 2017; 263:e154. http://www.ncbi.nlm.nih.gov/pubmed/?term=29365602
  11. Luginova Z, Tripoten M, Pogorelova O et al. Effect of short-term intensive rosuvastatin therapy on carotid plaque volume in very high cardiovascular risk patients: A three-dimensional ultrasound imaging study. Atherosclerosis 2017; 263:e40-e41. http://www.ncbi.nlm.nih.gov/pubmed/?term=29366103
  12. Kozlov S, Kchamchieva L, Tripoten M et al. Effect of intensive statin therapy on carotid plaque echogenicity in patients with nonobstructive asymptomatic carotid stenosis. Atherosclerosis 2017; 263:e147. http://www.ncbi.nlm.nih.gov/pubmed/?term=29365582
  13. Karlson BW, Jornten-Karlsson M, Xu Y et al. Rationale, design, and baseline characteristics of a randomised trial evaluating the effect of a smart phone based patient support tool on treatment duration in patients prescribed rosuvastatin in china (EHELP China). Atherosclerosis 2017; 263:e247-e248. http://www.ncbi.nlm.nih.gov/pubmed/?term=29365946
  14. Hong SJ, Choi SY, Han SH et al. Safety and tolerability of atorvastatin calcium anhydrous in Korean patients with dyslipidemia: An interim analysis from the lamp study. Atherosclerosis 2017; 263:e236. http://www.ncbi.nlm.nih.gov/pubmed/?term=29365909
  15. Gorzelak-Pabis P, Durma A, Trambowicz K et al. The association between atorvastatin and rosuvastatin use and sleep disturbance. Atherosclerosis 2017; 263:e238. http://www.ncbi.nlm.nih.gov/pubmed/?term=29365915
  16. Gocmen AY, Gumuslu S. Atorvastatin influences oxidative stress markers in hypercholesterolemic rats. Atherosclerosis 2017; 263:e162. http://www.ncbi.nlm.nih.gov/pubmed/?term=29365633
  17. Filatova A, Kuznetsova G, Shchinova A et al. Influence of short-term intensive atorvastatin therapy on lymphocyte and monocyte subpopulations and CCR2, CCR5, CX3CR1 and TLR4 expression in blood of patients with stable angina. Atherosclerosis 2017; 263:e112-e113. http://www.ncbi.nlm.nih.gov/pubmed/?term=29365463
  18. Bao JW, Sun B, Ma PP et al. Rosuvastatin inhibits inflammatory response and resists fibrosis after myocardial infarction. Eur Rev Med Pharmacol Sci 2018; 22:238-245. http://www.ncbi.nlm.nih.gov/pubmed/?term=29364492
  19. Aziz N, Sirojiddin K, Majid K. Influence of high doses of atorvastatin on myocardial stanning in acute myocardial infarction. Atherosclerosis 2017; 263:e245. http://www.ncbi.nlm.nih.gov/pubmed/?term=29365939
  20. Askri I, Kelbousi S, Sakly M, Attia N. Atorvastatin effect on phospholipid profile and distribution between lipoprotein fractions in type 2 diabetic patients with and without CAD. Atherosclerosis 2017; 263:e246. http://www.ncbi.nlm.nih.gov/pubmed/?term=29365941
  21. Alyavi A, Alyavi B, Uzokov J. Efficiency and safety of rosuvastatin in patients with metabolic syndrome. Atherosclerosis 2017; 263:e245. http://www.ncbi.nlm.nih.gov/pubmed/?term=29365938
  22. Takano J, Maeda K, Kusuhara H, Sugiyama Y. Organic anion transporting polypeptide 1a4 is responsible for the hepatic uptake of cardiac glycosides in mice. Drug metabolism and disposition: the biological fate of chemicals 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29348124
  23. Stolarczyk M, Apola A, Maslanka A et al. Spectrophotometric method for simultaneous determination of valsartan and substances from the group of statins in binary mixtures. Acta pharmaceutica (Zagreb, Croatia) 2017; 67:463-478. http://www.ncbi.nlm.nih.gov/pubmed/?term=29337671
  24. Mayyas F, Baydoun D, Ibdah R, Ibrahim K. Atorvastatin Reduces Plasma Inflammatory and Oxidant Biomarkers in Patients With Risk of Atherosclerotic Cardiovascular Disease. Journal of cardiovascular pharmacology and therapeutics 2018:1074248417753677. http://www.ncbi.nlm.nih.gov/pubmed/?term=29343081
  25. Fu N, Liang M, Yang S. High Loading Dose of Atorvastatin for the Prevention of Serum Creatinine and Cystatin C-Based Contrast-Induced Nephropathy Following Percutaneous Coronary Intervention. Angiology 2018:3319717750903. http://www.ncbi.nlm.nih.gov/pubmed/?term=29343076
  26. El-Shinnawy NA, Abd Elhalem SS, Haggag NZ, Badr G. Ameliorative role of camel whey protein and rosuvastatin on induced dyslipidemia in mice. Food & function 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29349446
  27. Al-Kuraishy HM, Al-Gareeb AI, Al-Buhadilly AK. Rosuvastatin Improves Vaspin Serum Levels in Obese Patients with Acute Coronary Syndrome. Diseases (Basel, Switzerland) 2018; 6. http://www.ncbi.nlm.nih.gov/pubmed/?term=29337850
  28. Zakrajsek J, Bevc-Cernilec K, Bohanec S, Urleb U. Optimization of UPLC Method for Simultaneous Determination of Rosuvastatin and Rosuvastatin Degradation Products. Acta chimica Slovenica 2017; 64:968-979. http://www.ncbi.nlm.nih.gov/pubmed/?term=29318320
  29. Szymanski FM, Platek AE, Rys A et al. Utilization of the lipid-lowering therapies in outpatient settings in Poland - epidemiological survey Economedica Dyslipidemia 2015. Kardiol Pol 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29313565
  30. Sun S, Wang R, Fan J et al. Effects of Danshen tablets on pharmacokinetics of atorvastatin calcium in rats and its potential mechanism. Pharmaceutical biology 2018; 56:104-108. http://www.ncbi.nlm.nih.gov/pubmed/?term=29322864
  31. Sai C, Li J, Yingbin X, Ruiyan M. Atorvastatin Prevents Postoperative Atrial Fibrillation for Patients undergoing Cardiac Surgery. Hellenic journal of cardiology : HJC = Hellenike kardiologike epitheorese 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29307691
  32. Rafeeq MM, Habib HS, Murad HAS et al. Effect of genetic polymorphisms in SREBF-SCAP pathway on therapeutic response to rosuvastatin in Saudi metabolic syndrome patients. Pharmacogenomics 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29318930
  33. Khan TJ, Ahmed YM, Zamzami MA et al. Effect of atorvastatin on the gut microbiota of high fat diet-induced hypercholesterolemic rats. Scientific reports 2018; 8:662. http://www.ncbi.nlm.nih.gov/pubmed/?term=29330433
  34. Kang J, Kim YC, Park JJ et al. Increased epicardial adipose tissue thickness is a predictor of new-onset diabetes mellitus in patients with coronary artery disease treated with high-intensity statins. Cardiovascular diabetology 2018; 17:10. http://www.ncbi.nlm.nih.gov/pubmed/?term=29325562
  35. Jones HM, Fang Z, Sun W et al. Atorvastatin exhibits anti-tumorigenic and anti-metastatic effects in ovarian cancer in vitro. American journal of cancer research 2017; 7:2478-2490. http://www.ncbi.nlm.nih.gov/pubmed/?term=29312801
  36. Chen CH, Cheng CY, Chen YC et al. Corrigendum to ' Rosuvastatin inhibits pressure-induced fibrotic responses via the expression regulation of prostacyclin and prostaglandin E 2 in rat renal tubular cells.': [European Journal of Pharmacology 700 (2013) 65-73]. Eur J Pharmacol 2018; 819:290. http://www.ncbi.nlm.nih.gov/pubmed/?term=29325908
  37. Arya S, Khakharia A, Binney ZO et al. Statins Have a Dose-Dependent Effect on Amputation and Survival in Peripheral Artery Disease Patients. Circulation 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29330214
  38. Acar D, Gulpembe M, Yildiz CG et al. The reno-protective effects of atorvastatin in crush syndrome and rhabdomyolysis:is there a dilemma? Turk J Med Sci 2017; 47:1920-1924. http://www.ncbi.nlm.nih.gov/pubmed/?term=29306258
  39. Vogt K, Mahajan-Thakur S, Wolf R et al. Release of Platelet-Derived Sphingosine-1-Phosphate Involves Multidrug Resistance Protein 4 (MRP4/ABCC4) and Is Inhibited by Statins. Thrombosis and haemostasis 2018; 118:132-142. http://www.ncbi.nlm.nih.gov/pubmed/?term=29304533
  40. Canepa M, Artom N, Ameri P et al. Short-term effect of rosuvastatin treatment on arterial stiffness in individuals with newly-diagnosed heterozygous familial hypercholesterolemia. Int J Cardiol 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29290422

Basic science

  1. Zhu B, Tang C. Atorvastatin upregulates expression of p16 and inhibits proliferation and migration of VSMCS via altered dna methylation. Atherosclerosis 2017; 263:e132. http://www.ncbi.nlm.nih.gov/pubmed/?term=29365530
  2. Zandl M, Fanaee-Danesh E, Gali CC et al. Interactions of simvastatin and APOJ with amyloid processing in cerebrovascular endothelial cells. Atherosclerosis 2017; 263:e85-e86. http://www.ncbi.nlm.nih.gov/pubmed/?term=29366247
  3. Wu F, Luo T, Mei Y et al. Simvastatin alters M1/M2 polarization of murine BV2 microglia via Notch signaling. Journal of neuroimmunology 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29361314
  4. Vladimirov S, Gojkovic T, Spasojevic-Kalimanovska V et al. Influence of LCAT and CETP activity on the reverse cholesterol transport and modification of HDL particles in statin-treated coronary artery disease patients and healthy subjects. Atherosclerosis 2017; 263:e217. http://www.ncbi.nlm.nih.gov/pubmed/?term=29365842
  5. Verma AK, Laha B, Pandey M et al. Cholesterol-lowering drug, in combination with chromium chloride, induces early apoptotic signals in intracellular L. donovani amastigotes, leading to death. Journal of biosciences 2017; 42:427-438. http://www.ncbi.nlm.nih.gov/pubmed/?term=29358556
  6. Uchiyama H, Tsujimoto M, Shimada N et al. Evaluation of Trace Elements in Augmentation of Statin-Induced Cytotoxicity in Uremic Serum-Exposed Human Rhabdomyosarcoma Cells. Toxins 2018; 10. http://www.ncbi.nlm.nih.gov/pubmed/?term=29370118
  7. Tzani A, Doulamis I, Konstantopoulos P et al. Proteomics discovery of biomarkers in statin-treated patients with advanced coronary artery disease. Atherosclerosis 2017; 263:e241. http://www.ncbi.nlm.nih.gov/pubmed/?term=29365926
  8. Singh P, Zhang Y, Sharma P et al. Statins decrease leptin expression in human white adipocytes. Physiological reports 2018; 6. http://www.ncbi.nlm.nih.gov/pubmed/?term=29372612
  9. Shahrezaee M, Oryan A, Bastami F et al. Comparative impact of systemic delivery of atorvastatin, simvastatin, and lovastatin on bone mineral density of the ovariectomized rats. Endocrine 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29372484
  10. Nikolic T, Zivkovic V, Jeremic N et al. Impact of atorvastatin and simvastatin on lipid and non-lipid biochemical risk factors in diet-induced hyperhomocisteinemia in wistar albino rats: A comparative study. Atherosclerosis 2017; 263:e136. http://www.ncbi.nlm.nih.gov/pubmed/?term=29365545
  11. Misaka S, Abe O, Sato H et al. Lack of pharmacokinetic interaction between fluvastatin and green tea in healthy volunteers. Eur J Clin Pharmacol 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29368187
  12. Gocmen AY, Gumuslu S. Atorvastatin influences oxidative stress markers in hypercholesterolemic rats. Atherosclerosis 2017; 263:e162. http://www.ncbi.nlm.nih.gov/pubmed/?term=29365633
  13. Defilippi C, Lo J, Christenson R et al. Novel mediators of statin effects on plaque in HIV: a proteomics approach. Aids 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29369166
  14. Cheng Y, Zheng H, Wang B et al. Sorafenib and fluvastatin synergistically alleviate hepatic fibrosis via inhibiting the TGFbeta1/Smad3 pathway. Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29373239
  15. Bao JW, Sun B, Ma PP et al. Rosuvastatin inhibits inflammatory response and resists fibrosis after myocardial infarction. Eur Rev Med Pharmacol Sci 2018; 22:238-245. http://www.ncbi.nlm.nih.gov/pubmed/?term=29364492
  16. Zhao L, Xiao Y, Xiu J et al. Protection against the Neurotoxic Effects of beta-Amyloid Peptide on Cultured Neuronal Cells by Lovastatin Involves Elevated Expression of alpha7 Nicotinic Acetylcholine Receptors and Activating Phosphorylation of Protein Kinases. The American journal of pathology 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29341888
  17. Stolarczyk M, Apola A, Maslanka A et al. Spectrophotometric method for simultaneous determination of valsartan and substances from the group of statins in binary mixtures. Acta pharmaceutica (Zagreb, Croatia) 2017; 67:463-478. http://www.ncbi.nlm.nih.gov/pubmed/?term=29337671
  18. Naveed S, Usmanghani K, Sana A et al. Estimation of simvastatin and cetirizine by RP-LC method: Application to freeze and thaw (FT) stability studies. Pak J Pharm Sci 2018; 31:137-141. http://www.ncbi.nlm.nih.gov/pubmed/?term=29348095
  19. Luput L, Licarete E, Drotar DM et al. In Vivo Double Targeting of C26 Colon Carcinoma Cells and Microenvironmental Protumor Processes Using Liposomal Simvastatin. Journal of Cancer 2018; 9:440-449. http://www.ncbi.nlm.nih.gov/pubmed/?term=29344291
  20. Liu Z, Zhang X, Xiao Q et al. Pretreatment Donors after Circulatory Death with Simvastatin Alleviates Liver Ischemia Reperfusion Injury through a KLF2-Dependent Mechanism in Rat. Oxidative medicine and cellular longevity 2017; 2017:3861914. http://www.ncbi.nlm.nih.gov/pubmed/?term=29348789
  21. El-Shinnawy NA, Abd Elhalem SS, Haggag NZ, Badr G. Ameliorative role of camel whey protein and rosuvastatin on induced dyslipidemia in mice. Food & function 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29349446
  22. Al-Kuraishy HM, Al-Gareeb AI, Al-Buhadilly AK. Rosuvastatin Improves Vaspin Serum Levels in Obese Patients with Acute Coronary Syndrome. Diseases (Basel, Switzerland) 2018; 6. http://www.ncbi.nlm.nih.gov/pubmed/?term=29337850
  23. Zakrajsek J, Bevc-Cernilec K, Bohanec S, Urleb U. Optimization of UPLC Method for Simultaneous Determination of Rosuvastatin and Rosuvastatin Degradation Products. Acta chimica Slovenica 2017; 64:968-979. http://www.ncbi.nlm.nih.gov/pubmed/?term=29318320
  24. Singh I, Samuvel DJ, Choi S et al. Combination therapy of lovastatin and AMPK activator improves mitochondrial and peroxisomal functions and clinical disease in EAE model. Immunology 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29331024
  25. Rebalka IA, Cao AW, Raleigh MJ et al. Statin Therapy Negatively Impacts Skeletal Muscle Regeneration and Cutaneous Wound Repair in Type 1 Diabetic Mice. Front Physiol 2017; 8:1088. http://www.ncbi.nlm.nih.gov/pubmed/?term=29311999
  26. Liu WH, Xu XH, Luo Q et al. Inhibition of the RhoA/Rho-associated, coiled-coil-containing protein kinase-1 pathway is involved in the therapeutic effects of simvastatin on pulmonary arterial hypertension. Clinical and experimental hypertension (New York, N.Y. : 1993) 2018:1-7. http://www.ncbi.nlm.nih.gov/pubmed/?term=29319354
  27. Kamal AHM, Chakrabarty JK, Udden SMN et al. Inflammatory Proteomic Network Analysis of Statin-treated and Lipopolysaccharide-activated Macrophages. Scientific reports 2018; 8:164. http://www.ncbi.nlm.nih.gov/pubmed/?term=29317699
  28. Jones HM, Fang Z, Sun W et al. Atorvastatin exhibits anti-tumorigenic and anti-metastatic effects in ovarian cancer in vitro. American journal of cancer research 2017; 7:2478-2490. http://www.ncbi.nlm.nih.gov/pubmed/?term=29312801
  29. Jha A, Ryu MH, Ojo OO et al. Prophylactic benefits of systemically delivered simvastatin treatment in a house dust mite challenged murine model of allergic asthma. Br J Pharmacol 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29318574
  30. Chen CH, Cheng CY, Chen YC et al. Corrigendum to ' Rosuvastatin inhibits pressure-induced fibrotic responses via the expression regulation of prostacyclin and prostaglandin E 2 in rat renal tubular cells.': [European Journal of Pharmacology 700 (2013) 65-73]. Eur J Pharmacol 2018; 819:290. http://www.ncbi.nlm.nih.gov/pubmed/?term=29325908
  31. Vogt K, Mahajan-Thakur S, Wolf R et al. Release of Platelet-Derived Sphingosine-1-Phosphate Involves Multidrug Resistance Protein 4 (MRP4/ABCC4) and Is Inhibited by Statins. Thrombosis and haemostasis 2018; 118:132-142. http://www.ncbi.nlm.nih.gov/pubmed/?term=29304533
  32. Soares DG, Zhang Z, Mohamed F et al. Simvastatin and nanofibrous poly(l-lactic acid) scaffolds to promote the odontogenic potential of dental pulp cells in an inflammatory environment. Acta biomaterialia 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29294374
  33. Koi C, Izumi H, Kurita T et al. Lovastatin induced Kruppel like factor 2 (KLF2), Kruppel like factor 6 (KLF6) and Ras homolog family member B (RHOB) genes and preferentially led to viability reduction of Cisplatin-resistant cells. Oncotarget 2017; 8:106429-106442. http://www.ncbi.nlm.nih.gov/pubmed/?term=29290960

Cancer

  1. Luput L, Licarete E, Drotar DM et al. In Vivo Double Targeting of C26 Colon Carcinoma Cells and Microenvironmental Protumor Processes Using Liposomal Simvastatin. Journal of Cancer 2018; 9:440-449. http://www.ncbi.nlm.nih.gov/pubmed/?term=29344291
  2. Jones HM, Fang Z, Sun W et al. Atorvastatin exhibits anti-tumorigenic and anti-metastatic effects in ovarian cancer in vitro. American journal of cancer research 2017; 7:2478-2490. http://www.ncbi.nlm.nih.gov/pubmed/?term=29312801
  3. Bang UC, Watanabe T, Bendtsen F. The relationship between the use of statins and mortality, severity, and pancreatic cancer in Danish patients with chronic pancreatitis. European journal of gastroenterology & hepatology 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29309396
  4. Koi C, Izumi H, Kurita T et al. Lovastatin induced Kruppel like factor 2 (KLF2), Kruppel like factor 6 (KLF6) and Ras homolog family member B (RHOB) genes and preferentially led to viability reduction of Cisplatin-resistant cells. Oncotarget 2017; 8:106429-106442. http://www.ncbi.nlm.nih.gov/pubmed/?term=29290960

Children

  1. Bogsrud MP, Langslet G, Wium C et al. Treatment goal attainment in children with familial hypercholesterolemia: A cohort study of 302 children in Norway. J Clin Lipidol 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29310990

Cost-effectiveness

  1. Salami JA, Warraich HJ, Valero-Elizondo J et al. National Trends in Nonstatin Use and Expenditures Among the US Adult Population From 2002 to 2013: Insights From Medical Expenditure Panel Survey. J Am Heart Assoc 2018; 7. http://www.ncbi.nlm.nih.gov/pubmed/?term=29358195
  2. Kodera S, Morita H, Kiyosue A et al. Cost-Effectiveness of Statin Plus Eicosapentaenoic Acid Combination Therapy for Cardiovascular Disease Prevention in Japanese Patients With Hypercholesterolemia- An Analysis Based on the Japan Eicosapentaenoic Acid Lipid Intervention Study (JELIS). Circulation journal : official journal of the Japanese Circulation Society 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29367520
  3. Borissov B, Urbich M, Georgieva B et al. Cost-effectiveness of evolocumab in treatment of heterozygous familial hypercholesterolaemia in Bulgaria: measuring health benefit by effectively treated patient-years. Journal of market access & health policy 2017; 5:1412753. http://www.ncbi.nlm.nih.gov/pubmed/?term=29321830

CVD

  1. Aziz N, Sirojiddin K, Majid K. Influence of high doses of atorvastatin on myocardial stanning in acute myocardial infarction. Atherosclerosis 2017; 263:e245. http://www.ncbi.nlm.nih.gov/pubmed/?term=29365939
  2. Chin KL, Wolfe R, Reid CM et al. Does Statin Benefits Patients with Heart Failure Undergoing Percutaneous Coronary Intervention? Findings from the Melbourne Interventional Group Registry. Cardiovasc Drugs Ther 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29349644
  3. Acampa M, Lazzerini PE, Guideri F et al. Previous use of statins and atrial electrical remodeling in patients with cryptogenic stroke. Cardiovascular & hematological disorders drug targets 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29332603
  4. Tsujimoto T, Kajio H. Favorable effects of statins in the treatment of heart failure with preserved ejection fraction in patients without ischemic heart disease. Int J Cardiol 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29307549

Endothelium/inflammation

  1. Nizomov A, Kenjaev S. Effect of high-dose atorvastatin on lipid spectrum and inflammation in acute myocardial infarction. Atherosclerosis 2017; 263:e245-e246. http://www.ncbi.nlm.nih.gov/pubmed/?term=29365940
  2. Mark L, Harangi M, Paragh G. [The labyrinth of residual risk: reduction of the remaining lipid and inflammation risk in the prevention of atherosclerosis]. Orvosi hetilap 2018; 159:124-130. http://www.ncbi.nlm.nih.gov/pubmed/?term=29353502
  3. Li GM, Zhao J, Li B et al. The anti-inflammatory effects of statins on patients with rheumatoid arthritis: A systemic review and meta-analysis of 15 randomized controlled trials. Autoimmunity reviews 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29353098
  4. Klimushina M, Gumanova N, Gorshkov A et al. Marker of endothelial function, endothelin, is associated with gender-dependent response to statin therapy in patients with coronary atherosclerosis. Atherosclerosis 2017; 263:e281. http://www.ncbi.nlm.nih.gov/pubmed/?term=29366062
  5. Filatova A, Kuznetsova G, Shchinova A et al. Influence of short-term intensive atorvastatin therapy on lymphocyte and monocyte subpopulations and CCR2, CCR5, CX3CR1 and TLR4 expression in blood of patients with stable angina. Atherosclerosis 2017; 263:e112-e113. http://www.ncbi.nlm.nih.gov/pubmed/?term=29365463
  6. Defilippi C, Lo J, Christenson R et al. Novel mediators of statin effects on plaque in HIV: a proteomics approach. Aids 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29369166
  7. Bao JW, Sun B, Ma PP et al. Rosuvastatin inhibits inflammatory response and resists fibrosis after myocardial infarction. Eur Rev Med Pharmacol Sci 2018; 22:238-245. http://www.ncbi.nlm.nih.gov/pubmed/?term=29364492
  8. Mayyas F, Baydoun D, Ibdah R, Ibrahim K. Atorvastatin Reduces Plasma Inflammatory and Oxidant Biomarkers in Patients With Risk of Atherosclerotic Cardiovascular Disease. Journal of cardiovascular pharmacology and therapeutics 2018:1074248417753677. http://www.ncbi.nlm.nih.gov/pubmed/?term=29343081
  9. Kamal AHM, Chakrabarty JK, Udden SMN et al. Inflammatory Proteomic Network Analysis of Statin-treated and Lipopolysaccharide-activated Macrophages. Scientific reports 2018; 8:164. http://www.ncbi.nlm.nih.gov/pubmed/?term=29317699

Ethnicity

  1. Ouyang XJ, Zhang YQ, Chen JH et al. Situational Analysis of Low-density Lipoprotein Cholesterol Control and the Use of Statin Therapy in Diabetes Patients Treated in Community Hospitals in Nanjing, China. Chinese medical journal 2018; 131:295-300. http://www.ncbi.nlm.nih.gov/pubmed/?term=29363644
  2. Kodera S, Morita H, Kiyosue A et al. Cost-Effectiveness of Statin Plus Eicosapentaenoic Acid Combination Therapy for Cardiovascular Disease Prevention in Japanese Patients With Hypercholesterolemia- An Analysis Based on the Japan Eicosapentaenoic Acid Lipid Intervention Study (JELIS). Circulation journal : official journal of the Japanese Circulation Society 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29367520
  3. Hong SJ, Choi SY, Han SH et al. Safety and tolerability of atorvastatin calcium anhydrous in Korean patients with dyslipidemia: An interim analysis from the lamp study. Atherosclerosis 2017; 263:e236. http://www.ncbi.nlm.nih.gov/pubmed/?term=29365909
  4. Yu X, Zhang J, Gu Y et al. CHILD Syndrome Mimicking Verrucous Nevus in a Chinese Patient Responded Well to The Topical Therapy of Compound of Simvastatin and Cholesterol. Journal of the European Academy of Dermatology and Venereology : JEADV 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29341259
  5. Rafeeq MM, Habib HS, Murad HAS et al. Effect of genetic polymorphisms in SREBF-SCAP pathway on therapeutic response to rosuvastatin in Saudi metabolic syndrome patients. Pharmacogenomics 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29318930
  6. Zuo HJ, Wang WH, Deng LQ, Su JL. Control of cardiovascular disease risk factors among patients with type II diabetes in a primary-care setting in Beijing. Journal of the American Society of Hypertension : JASH 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29289467
  7. Jiang S, Venners SA, Li K et al. Effect modification by region in the associations of LEP G2548A and LEPR Q223R polymorphisms with statin-induced CK elevation. Oncotarget 2017; 8:107565-107576. http://www.ncbi.nlm.nih.gov/pubmed/?term=29296187
  8. Dai YY, Huang ZX, Liu XT, Wang QZ. [Risk factors for recurrence of large atherosclerotic cerebral infarction]. Nan fang yi ke da xue xue bao = Journal of Southern Medical University 2017; 37:1678-1682. http://www.ncbi.nlm.nih.gov/pubmed/?term=29292265 

FH

  1. Teramoto T, Kai T, Ozaki A et al. Treatment Patterns and Lipid Profile in Patients with Familial Hypercholesterolemia in Japan. J Atheroscler Thromb 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29353825
  2. Susekov A, Meshkov A, Scherbakova M. Fast regression of xanthomatosis in patient with homogous FH after intensive therapy with statin, ezetimibe and PCSK9 inhibitor evalocumab- the case. Atherosclerosis 2017; 263:e229-e230. http://www.ncbi.nlm.nih.gov/pubmed/?term=29365883
  3. D'Erasmo L, Minicocci I, Nicolucci A et al. Autosomal Recessive Hypercholesterolemia: Long-Term Cardiovascular Outcomes. J Am Coll Cardiol 2018; 71:279-288. http://www.ncbi.nlm.nih.gov/pubmed/?term=29348020
  4. Bogsrud MP, Langslet G, Wium C et al. Treatment goal attainment in children with familial hypercholesterolemia: A cohort study of 302 children in Norway. J Clin Lipidol 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29310990
  5. Canepa M, Artom N, Ameri P et al. Short-term effect of rosuvastatin treatment on arterial stiffness in individuals with newly-diagnosed heterozygous familial hypercholesterolemia. Int J Cardiol 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29290422

Genetics

  1. Pechlivanis S, Moebus S, Lehmann N et al. Pharmacogenetic association of blood-lipid related genetic variants with 5-year progression of coronary artery calcification following the treatment with statin in the Heinz Nixdorf Recall study. Atherosclerosis 2017; 263:e278. http://www.ncbi.nlm.nih.gov/pubmed/?term=29366052
  2. Bakar NS, Neely D, Avery P et al. Patient specific genetic and clinical factors are associated with statin-related myotoxicity of moderate severity: A case-control study. Atherosclerosis 2017; 263:e243. http://www.ncbi.nlm.nih.gov/pubmed/?term=29365932
  3. Larson EA. Statin Pharmacogenetics: Moving from Toxicity to Efficacy. South Dakota medicine : the journal of the South Dakota State Medical Association 2017; 70:540-541. http://www.ncbi.nlm.nih.gov/pubmed/?term=29334441
  4. Rafeeq MM, Habib HS, Murad HAS et al. Effect of genetic polymorphisms in SREBF-SCAP pathway on therapeutic response to rosuvastatin in Saudi metabolic syndrome patients. Pharmacogenomics 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29318930
  5. Jiang S, Venners SA, Li K et al. Effect modification by region in the associations of LEP G2548A and LEPR Q223R polymorphisms with statin-induced CK elevation. Oncotarget 2017; 8:107565-107576. http://www.ncbi.nlm.nih.gov/pubmed/?term=29296187
  6. Angelini S, Rosticci M, Massimo G et al. Relationship between Lipid Phenotypes, Overweight, Lipid Lowering Drug Response and KIF6 and HMG-CoA Genotypes in a Subset of the Brisighella Heart Study Population. Int J Mol Sci 2017; 19. http://www.ncbi.nlm.nih.gov/pubmed/?term=29295555

Guidelines

  1. Wang WT, Hellkamp A, Doll JA et al. Lipid Testing and Statin Dosing After Acute Myocardial Infarction. J Am Heart Assoc 2018; 7. http://www.ncbi.nlm.nih.gov/pubmed/?term=29371200
  2. Toth PP, Bays H, Farnier M et al. A comparison of the attainment of guideline-recommended LDL-C lowering with statin and ezetimibe+statin therapies. Atherosclerosis 2017; 263:e240-e241. http://www.ncbi.nlm.nih.gov/pubmed/?term=29365924
  3. Okuyama H, Hamazaki T, Hama R et al. A Critical Review of the Consensus Statement from the European Atherosclerosis Society Consensus Panel 2017. Pharmacology 2018; 101:184-218. http://www.ncbi.nlm.nih.gov/pubmed/?term=29353277
  4. Mortensen MB, Nordestgaard BG. Comparison of Five Major Guidelines for Statin Use in Primary Prevention in a Contemporary General Population. Annals of internal medicine 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29297004

LDL- related parameters

  1. Zodda D, Giammona R, Schifilliti S. Treatment Strategy for Dyslipidemia in Cardiovascular Disease Prevention: Focus on Old and New Drugs. Pharmacy (Basel, Switzerland) 2018; 6. http://www.ncbi.nlm.nih.gov/pubmed/?term=29361723
  2. Wang WT, Hellkamp A, Doll JA et al. Lipid Testing and Statin Dosing After Acute Myocardial Infarction. J Am Heart Assoc 2018; 7. http://www.ncbi.nlm.nih.gov/pubmed/?term=29371200
  3. Ozerova I, Metelskaya V, Gavrilova N. Changes in subfractional distribution of apolipoprotein B-containing lipoproteins in patients with coronary atherosclerosis on statin therapy: Gender differences. Atherosclerosis 2017; 263:e190. http://www.ncbi.nlm.nih.gov/pubmed/?term=29365737
  4. Ouyang XJ, Zhang YQ, Chen JH et al. Situational Analysis of Low-density Lipoprotein Cholesterol Control and the Use of Statin Therapy in Diabetes Patients Treated in Community Hospitals in Nanjing, China. Chinese medical journal 2018; 131:295-300. http://www.ncbi.nlm.nih.gov/pubmed/?term=29363644
  5. Meikle P, Barlow C, Nestel P et al. Decreases in plasma phosphatidylinositol species partially explain the reduction in cardiovascular events after pravastatin therapy in secondary prevention. Atherosclerosis 2017; 263:e239. http://www.ncbi.nlm.nih.gov/pubmed/?term=29365917
  6. Gojkovic T, Vladimirov S, Spasojevic-Kalimanovska V et al. Association of LDL phenotypes with cholesterol synthesis and HDL subclasses in statin-treated coronary artery disease patients and healthy subjects. Atherosclerosis 2017; 263:e205. http://www.ncbi.nlm.nih.gov/pubmed/?term=29365796
  7. Seo YH, Seo DJ, Song IG et al. Rationale of decreasing low-density lipoprotein cholesterol below 70 mg/dL in patients with coronary artery disease: A retrospective virtual histology. Intravascular ultrasound study. Cardiology journal 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29341060

Lifestyle

  1. Mehrad H, Mokhtari-Dizaji M, Ghanaati H. Effect of high-dose atorvastatin therapy accompanied by discontinuation of cholesterol-rich diet on color-doppler ultrasonography parameters of atherosclerotic carotid artery. Atherosclerosis 2017; 263:e246. http://www.ncbi.nlm.nih.gov/pubmed/?term=29365942
  2. Khan TJ, Ahmed YM, Zamzami MA et al. Effect of atorvastatin on the gut microbiota of high fat diet-induced hypercholesterolemic rats. Scientific reports 2018; 8:662. http://www.ncbi.nlm.nih.gov/pubmed/?term=29330433
  3. Angelini S, Rosticci M, Massimo G et al. Relationship between Lipid Phenotypes, Overweight, Lipid Lowering Drug Response and KIF6 and HMG-CoA Genotypes in a Subset of the Brisighella Heart Study Population. Int J Mol Sci 2017; 19. http://www.ncbi.nlm.nih.gov/pubmed/?term=29295555

Meta-analyses

  1. Li GM, Zhao J, Li B et al. The anti-inflammatory effects of statins on patients with rheumatoid arthritis: A systemic review and meta-analysis of 15 randomized controlled trials. Autoimmunity reviews 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29353098
  2. Feng WW, Kuang SY, Tu C et al. Natural products berberine and curcumin exhibited better ameliorative effects on rats with non-alcohol fatty liver disease than lovastatin. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 2018; 99:325-333. http://www.ncbi.nlm.nih.gov/pubmed/?term=29353208
  3. Esteve-Valverde E, Ferrer-Oliveras R, Gil-Aliberas N et al. Pravastatin for Preventing and Treating Preeclampsia: A Systematic Review. Obstetrical & gynecological survey 2018; 73:40-55. http://www.ncbi.nlm.nih.gov/pubmed/?term=29368790
  4. Casula M, Mozzanica F, Scotti L et al. Statin use and risk of new-onset diabetes: a meta-analysis of observational studies. Atherosclerosis 2017; 263:e262-e263. http://www.ncbi.nlm.nih.gov/pubmed/?term=29365998
  5. Mills EP, Brown KPD, Smith JD et al. Treating nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus: a review of efficacy and safety. Therapeutic advances in endocrinology and metabolism 2018; 9:15-28. http://www.ncbi.nlm.nih.gov/pubmed/?term=29344336
  6. Martin-Ruiz E, Olry-de-Labry-Lima A, Ocana-Riola R, Epstein D. Systematic Review of the Effect of Adherence to Statin Treatment on Critical Cardiovascular Events and Mortality in Primary Prevention. Journal of cardiovascular pharmacology and therapeutics 2018:1074248417745357. http://www.ncbi.nlm.nih.gov/pubmed/?term=29343082
  7. Sai C, Li J, Yingbin X, Ruiyan M. Atorvastatin Prevents Postoperative Atrial Fibrillation for Patients undergoing Cardiac Surgery. Hellenic journal of cardiology : HJC = Hellenike kardiologike epitheorese 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29307691
  8. Qiu C, Zhou Q, Li X et al. High circulating proprotein convertase subtilisin/Kexin type 9 concentration associates with cardiovascular risk: A meta-analysis of cohort studies. Medicine (Baltimore) 2017; 96:e8848. http://www.ncbi.nlm.nih.gov/pubmed/?term=29310364
  9. Zheng-Lin B, Ortiz A. Lipid Management in Chronic Kidney Disease: Systematic Review of PCSK9 Targeting. Drugs 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29299849
  10. Lamarche F, Agharazii M, Nadeau-Fredette AC et al. Central and Brachial Blood Pressures, Statins, and Low-Density Lipoprotein Cholesterol: A Mediation Analysis. Hypertension 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29295849

Metabolic Syndrome - Diabetes

  1. Yasuda H, Fujiwara A, Komiya S, Haze T. Effects of rosuvastatin add-on treatment on hyperlipidemia in type 2 diabetic patients with chronic kidney disease receiving ethyl icosapentate. Atherosclerosis 2017; 263:e241-e242. http://www.ncbi.nlm.nih.gov/pubmed/?term=29365927
  2. Uzokov J, Alyavi A, Alyavi B. Influence of combination therapy of rosuvastatin and telmisartan on vascular and metabolic profile in hypercholesterolemic patients with metabolic syndrome. Atherosclerosis 2017; 263:e241. http://www.ncbi.nlm.nih.gov/pubmed/?term=29365928
  3. Ouyang XJ, Zhang YQ, Chen JH et al. Situational Analysis of Low-density Lipoprotein Cholesterol Control and the Use of Statin Therapy in Diabetes Patients Treated in Community Hospitals in Nanjing, China. Chinese medical journal 2018; 131:295-300. http://www.ncbi.nlm.nih.gov/pubmed/?term=29363644
  4. Askri I, Kelbousi S, Sakly M, Attia N. Atorvastatin effect on phospholipid profile and distribution between lipoprotein fractions in type 2 diabetic patients with and without CAD. Atherosclerosis 2017; 263:e246. http://www.ncbi.nlm.nih.gov/pubmed/?term=29365941
  5. Alyavi A, Alyavi B, Uzokov J. Efficiency and safety of rosuvastatin in patients with metabolic syndrome. Atherosclerosis 2017; 263:e245. http://www.ncbi.nlm.nih.gov/pubmed/?term=29365938
  6. Rebalka IA, Cao AW, Raleigh MJ et al. Statin Therapy Negatively Impacts Skeletal Muscle Regeneration and Cutaneous Wound Repair in Type 1 Diabetic Mice. Front Physiol 2017; 8:1088. http://www.ncbi.nlm.nih.gov/pubmed/?term=29311999
  7. Kang J, Kim YC, Park JJ et al. Increased epicardial adipose tissue thickness is a predictor of new-onset diabetes mellitus in patients with coronary artery disease treated with high-intensity statins. Cardiovascular diabetology 2018; 17:10. http://www.ncbi.nlm.nih.gov/pubmed/?term=29325562

New Treatments

  1. Zodda D, Giammona R, Schifilliti S. Treatment Strategy for Dyslipidemia in Cardiovascular Disease Prevention: Focus on Old and New Drugs. Pharmacy (Basel, Switzerland) 2018; 6. http://www.ncbi.nlm.nih.gov/pubmed/?term=29361723
  2. Waldmann E, Bamberger C, Parhofer KG. Statin intolerance is the main indication for PCSK9 inhibition in clinical practice. Atherosclerosis 2017; 263:e80. http://www.ncbi.nlm.nih.gov/pubmed/?term=29366231
  3. Susekov A, Meshkov A, Scherbakova M. Fast regression of xanthomatosis in patient with homogous FH after intensive therapy with statin, ezetimibe and PCSK9 inhibitor evalocumab- the case. Atherosclerosis 2017; 263:e229-e230. http://www.ncbi.nlm.nih.gov/pubmed/?term=29365883
  4. Reiner Z. PCSK9 inhibitors in clinical practice: Expectations and reality. Atherosclerosis 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29366497
  5. Mehrad H, Farhoudi M, Foletti A. Confocal dual- pulse electrohydraulic shock wave therapy for advanced atherosclerosis regression accompanied by atorvastatin- loaded microbubbles administration. Atherosclerosis 2017; 263:e154. http://www.ncbi.nlm.nih.gov/pubmed/?term=29365602
  6. Kasichayanula S, Grover A, Emery MG et al. Clinical Pharmacokinetics and Pharmacodynamics of Evolocumab, a PCSK9 Inhibitor. Clinical pharmacokinetics 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29353350
  7. Ali A, Costanzo P, Hoye A. Proprotein convertase subtilisin/kexin type 9 inhibition in cardiovascular prevention. Current pharmaceutical design 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29332570
  8. Qiu C, Zhou Q, Li X et al. High circulating proprotein convertase subtilisin/Kexin type 9 concentration associates with cardiovascular risk: A meta-analysis of cohort studies. Medicine (Baltimore) 2017; 96:e8848. http://www.ncbi.nlm.nih.gov/pubmed/?term=29310364
  9. Borissov B, Urbich M, Georgieva B et al. Cost-effectiveness of evolocumab in treatment of heterozygous familial hypercholesterolaemia in Bulgaria: measuring health benefit by effectively treated patient-years. Journal of market access & health policy 2017; 5:1412753. http://www.ncbi.nlm.nih.gov/pubmed/?term=29321830
  10. Chen IC, Tseng WK, Li YH et al. Effect of cilostazol on plasma levels of proprotein convertase subtilisin/kexin type 9. Oncotarget 2017; 8:108042-108053. http://www.ncbi.nlm.nih.gov/pubmed/?term=29296222

PAD and statins

  1. Cea-Soriano L, Fowkes FGR, Johansson S et al. Time trends in peripheral artery disease incidence, prevalence and secondary preventive therapy: a cohort study in The Health Improvement Network in the UK. BMJ Open 2018; 8:e018184. http://www.ncbi.nlm.nih.gov/pubmed/?term=29358428
  2. Jones WS, Patel MR. Antithrombotic Therapy in Peripheral Artery Disease: Generating and Translating Evidence Into Practice. J Am Coll Cardiol 2018; 71:352-362. http://www.ncbi.nlm.nih.gov/pubmed/?term=29348028
  3. Poredos P, Poredos P. Peripheral arterial occlusive disease and perioperative risk. International angiology : a journal of the International Union of Angiology 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29327897
  4. Arya S, Khakharia A, Binney ZO et al. Statins Have a Dose-Dependent Effect on Amputation and Survival in Peripheral Artery Disease Patients. Circulation 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29330214

Pleiotropic effects of statins

  1. Esteve-Valverde E, Ferrer-Oliveras R, Gil-Aliberas N et al. Pravastatin for Preventing and Treating Preeclampsia: A Systematic Review. Obstetrical & gynecological survey 2018; 73:40-55. http://www.ncbi.nlm.nih.gov/pubmed/?term=29368790
  2. Mills EP, Brown KPD, Smith JD et al. Treating nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus: a review of efficacy and safety. Therapeutic advances in endocrinology and metabolism 2018; 9:15-28. http://www.ncbi.nlm.nih.gov/pubmed/?term=29344336
  3. Liu Z, Zhang X, Xiao Q et al. Pretreatment Donors after Circulatory Death with Simvastatin Alleviates Liver Ischemia Reperfusion Injury through a KLF2-Dependent Mechanism in Rat. Oxidative medicine and cellular longevity 2017; 2017:3861914. http://www.ncbi.nlm.nih.gov/pubmed/?term=29348789
  4. Krysiak R, Szkrobka W, Okopien B. Moderate-dose simvastatin therapy potentiates the effect of vitamin D on thyroid autoimmunity in levothyroxine-treated women with Hashimoto's thyroiditis and vitamin D insufficiency. Pharmacological reports : PR 2017; 70:93-97. http://www.ncbi.nlm.nih.gov/pubmed/?term=29331793
  5. Fu N, Liang M, Yang S. High Loading Dose of Atorvastatin for the Prevention of Serum Creatinine and Cystatin C-Based Contrast-Induced Nephropathy Following Percutaneous Coronary Intervention. Angiology 2018:3319717750903. http://www.ncbi.nlm.nih.gov/pubmed/?term=29343076
  6. Acampa M, Lazzerini PE, Guideri F et al. Previous use of statins and atrial electrical remodeling in patients with cryptogenic stroke. Cardiovascular & hematological disorders drug targets 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29332603
  7. Schreiber K, Sciascia S, de Groot PG et al. Antiphospholipid syndrome. Nature reviews. Disease primers 2018; 4:17103. http://www.ncbi.nlm.nih.gov/pubmed/?term=29321641
  8. Sai C, Li J, Yingbin X, Ruiyan M. Atorvastatin Prevents Postoperative Atrial Fibrillation for Patients undergoing Cardiac Surgery. Hellenic journal of cardiology : HJC = Hellenike kardiologike epitheorese 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29307691
  9. Liu WH, Xu XH, Luo Q et al. Inhibition of the RhoA/Rho-associated, coiled-coil-containing protein kinase-1 pathway is involved in the therapeutic effects of simvastatin on pulmonary arterial hypertension. Clinical and experimental hypertension (New York, N.Y. : 1993) 2018:1-7. http://www.ncbi.nlm.nih.gov/pubmed/?term=29319354
  10. Jha A, Ryu MH, Ojo OO et al. Prophylactic benefits of systemically delivered simvastatin treatment in a house dust mite challenged murine model of allergic asthma. Br J Pharmacol 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29318574
  11. Acar D, Gulpembe M, Yildiz CG et al. The reno-protective effects of atorvastatin in crush syndrome and rhabdomyolysis:is there a dilemma? Turk J Med Sci 2017; 47:1920-1924. http://www.ncbi.nlm.nih.gov/pubmed/?term=29306258
  12. Lamarche F, Agharazii M, Nadeau-Fredette AC et al. Central and Brachial Blood Pressures, Statins, and Low-Density Lipoprotein Cholesterol: A Mediation Analysis. Hypertension 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29295849

Primary Prevention

  1. Huesch MD. Association of Baseline Statin Use Among Older Adults Without Clinical Cardiovascular Disease in the SPRINT Trial. JAMA Intern Med 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29356825
  2. Regenold WT. Risks of Statins for Lower-Risk Individuals. Jama 2018; 319:309-310. http://www.ncbi.nlm.nih.gov/pubmed/?term=29340669
  3. Krumholz HM. Risks of Statins for Lower-Risk Individuals-Reply. Jama 2018; 319:310. http://www.ncbi.nlm.nih.gov/pubmed/?term=29340673
  4. Mortensen MB, Falk E. Primary Prevention With Statins in the Elderly. J Am Coll Cardiol 2018; 71:85-94. http://www.ncbi.nlm.nih.gov/pubmed/?term=29301631

Registry data

  1. Hamada T, Khalaf N, Yuan C et al. Statin use and pancreatic cancer risk in two prospective cohort studies. Journal of gastroenterology 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29362938
  2. Martin-Ruiz E, Olry-de-Labry-Lima A, Ocana-Riola R, Epstein D. Systematic Review of the Effect of Adherence to Statin Treatment on Critical Cardiovascular Events and Mortality in Primary Prevention. Journal of cardiovascular pharmacology and therapeutics 2018:1074248417745357. http://www.ncbi.nlm.nih.gov/pubmed/?term=29343082
  3. Szymanski FM, Platek AE, Rys A et al. Utilization of the lipid-lowering therapies in outpatient settings in Poland - epidemiological survey Economedica Dyslipidemia 2015. Kardiol Pol 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29313565
  4. Bogsrud MP, Langslet G, Wium C et al. Treatment goal attainment in children with familial hypercholesterolemia: A cohort study of 302 children in Norway. J Clin Lipidol 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29310990
  5. Bang UC, Watanabe T, Bendtsen F. The relationship between the use of statins and mortality, severity, and pancreatic cancer in Danish patients with chronic pancreatitis. European journal of gastroenterology & hepatology 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29309396
  6. Zuo HJ, Wang WH, Deng LQ, Su JL. Control of cardiovascular disease risk factors among patients with type II diabetes in a primary-care setting in Beijing. Journal of the American Society of Hypertension : JASH 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29289467
  7. Zheng-Lin B, Ortiz A. Lipid Management in Chronic Kidney Disease: Systematic Review of PCSK9 Targeting. Drugs 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29299849
  8. Dai YY, Huang ZX, Liu XT, Wang QZ. [Risk factors for recurrence of large atherosclerotic cerebral infarction]. Nan fang yi ke da xue xue bao = Journal of Southern Medical University 2017; 37:1678-1682. http://www.ncbi.nlm.nih.gov/pubmed/?term=29292265
  9. Angelini S, Rosticci M, Massimo G et al. Relationship between Lipid Phenotypes, Overweight, Lipid Lowering Drug Response and KIF6 and HMG-CoA Genotypes in a Subset of the Brisighella Heart Study Population. Int J Mol Sci 2017; 19. http://www.ncbi.nlm.nih.gov/pubmed/?term=29295555
  10. Alfian SD, Worawutputtapong P, Schuiling-Veninga CC et al. Pharmacy-based predictors of non-persistence and non-adherence to statin treatment among patients on oral diabetes medication in the Netherlands. Current medical research and opinion 2018:1-17. http://www.ncbi.nlm.nih.gov/pubmed/?term=29292657

Renal Disease

  1. Yasuda H, Fujiwara A, Komiya S, Haze T. Effects of rosuvastatin add-on treatment on hyperlipidemia in type 2 diabetic patients with chronic kidney disease receiving ethyl icosapentate. Atherosclerosis 2017; 263:e241-e242. http://www.ncbi.nlm.nih.gov/pubmed/?term=29365927
  2. Ong KL, Waters DD, Fayyad R et al. Relationship of High-Density Lipoprotein Cholesterol With Renal Function in Patients Treated With Atorvastatin. J Am Heart Assoc 2018; 7. http://www.ncbi.nlm.nih.gov/pubmed/?term=29358194
  3. Fu N, Liang M, Yang S. High Loading Dose of Atorvastatin for the Prevention of Serum Creatinine and Cystatin C-Based Contrast-Induced Nephropathy Following Percutaneous Coronary Intervention. Angiology 2018:3319717750903. http://www.ncbi.nlm.nih.gov/pubmed/?term=29343076
  4. Raman VK, Geladari E, Papademetriou V. Is statin therapy safe and effective in patients with chronic Kidney disease? Current pharmaceutical design 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29318962
  5. Acar D, Gulpembe M, Yildiz CG et al. The reno-protective effects of atorvastatin in crush syndrome and rhabdomyolysis:is there a dilemma? Turk J Med Sci 2017; 47:1920-1924. http://www.ncbi.nlm.nih.gov/pubmed/?term=29306258
  6. Zheng-Lin B, Ortiz A. Lipid Management in Chronic Kidney Disease: Systematic Review of PCSK9 Targeting. Drugs 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29299849

Reviews

  1. Jones WS, Patel MR. Antithrombotic Therapy in Peripheral Artery Disease: Generating and Translating Evidence Into Practice. J Am Coll Cardiol 2018; 71:352-362. http://www.ncbi.nlm.nih.gov/pubmed/?term=29348028
  2. D'Erasmo L, Minicocci I, Nicolucci A et al. Autosomal Recessive Hypercholesterolemia: Long-Term Cardiovascular Outcomes. J Am Coll Cardiol 2018; 71:279-288. http://www.ncbi.nlm.nih.gov/pubmed/?term=29348020
  3. Ali A, Costanzo P, Hoye A. Proprotein convertase subtilisin/kexin type 9 inhibition in cardiovascular prevention. Current pharmaceutical design 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29332570
  4. Toth PP, Patti AM, Giglio RV et al. Management of Statin Intolerance in 2018: Still More Questions Than Answers. Am J Cardiovasc Drugs 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29318532
  5. Schreiber K, Sciascia S, de Groot PG et al. Antiphospholipid syndrome. Nature reviews. Disease primers 2018; 4:17103. http://www.ncbi.nlm.nih.gov/pubmed/?term=29321641
  6. Ruscica M, Macchi C, Pavanello C et al. Appropriateness of statin prescription in the elderly. Eur J Intern Med 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29310996
  7. Raman VK, Geladari E, Papademetriou V. Is statin therapy safe and effective in patients with chronic Kidney disease? Current pharmaceutical design 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29318962
  8. Poredos P, Poredos P. Peripheral arterial occlusive disease and perioperative risk. International angiology : a journal of the International Union of Angiology 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29327897
  9. Wooten JM. A Brief Drug Class Review: Considerations for Statin Use, Toxicity, and Drug Interactions. Southern medical journal 2018; 111:39-44. http://www.ncbi.nlm.nih.gov/pubmed/?term=29298368
  10. Mortensen MB, Nordestgaard BG. Comparison of Five Major Guidelines for Statin Use in Primary Prevention in a Contemporary General Population. Annals of internal medicine 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29297004
  11. Mortensen MB, Falk E. Primary Prevention With Statins in the Elderly. J Am Coll Cardiol 2018; 71:85-94. http://www.ncbi.nlm.nih.gov/pubmed/?term=29301631

Safety and side effects

  1. Ward NC, Pang J, Ryan JDM, Watts GF. Nutraceuticals in the management of patients with statin-associated muscle symptoms, with a note on real-world experience. Clin Cardiol 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29363784
  2. Waldmann E, Bamberger C, Parhofer KG. Statin intolerance is the main indication for PCSK9 inhibition in clinical practice. Atherosclerosis 2017; 263:e80. http://www.ncbi.nlm.nih.gov/pubmed/?term=29366231
  3. Vrablik M, Catapano A, Wiklund O et al. Clinician interview results about the experiences of their patients who report side effects with statin treatment. Atherosclerosis 2017; 263:e247. http://www.ncbi.nlm.nih.gov/pubmed/?term=29365945
  4. Stock JK. Update on SAMS: Statin-associated muscle symptoms. Atherosclerosis 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29361270
  5. Hamada T, Khalaf N, Yuan C et al. Statin use and pancreatic cancer risk in two prospective cohort studies. Journal of gastroenterology 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29362938
  6. Gorzelak-Pabis P, Durma A, Trambowicz K et al. The association between atorvastatin and rosuvastatin use and sleep disturbance. Atherosclerosis 2017; 263:e238. http://www.ncbi.nlm.nih.gov/pubmed/?term=29365915
  7. Casula M, Mozzanica F, Scotti L et al. Statin use and risk of new-onset diabetes: a meta-analysis of observational studies. Atherosclerosis 2017; 263:e262-e263. http://www.ncbi.nlm.nih.gov/pubmed/?term=29365998
  8. Benczur B, Herczeg B. Safety of long-term statin therapy: Data from real-world observation in subjects at very high risk. Atherosclerosis 2017; 263:e246. http://www.ncbi.nlm.nih.gov/pubmed/?term=29365943
  9. Barkas F, Elisaf M, Liberopoulos E et al. Metabolic markers to predict incident diabetes in statin-treated individuals. Atherosclerosis 2017; 263:e259. http://www.ncbi.nlm.nih.gov/pubmed/?term=29365987
  10. Bakar NS, Neely D, Avery P et al. Patient specific genetic and clinical factors are associated with statin-related myotoxicity of moderate severity: A case-control study. Atherosclerosis 2017; 263:e243. http://www.ncbi.nlm.nih.gov/pubmed/?term=29365932
  11. Yu X, Zhang J, Gu Y et al. CHILD Syndrome Mimicking Verrucous Nevus in a Chinese Patient Responded Well to The Topical Therapy of Compound of Simvastatin and Cholesterol. Journal of the European Academy of Dermatology and Venereology : JEADV 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29341259
  12. Wiewel MA, Scicluna BP, van Vught LA et al. The host response in critically ill sepsis patients on statin therapy: a prospective observational study. Ann Intensive Care 2018; 8:9. http://www.ncbi.nlm.nih.gov/pubmed/?term=29349709
  13. Takano J, Maeda K, Kusuhara H, Sugiyama Y. Organic anion transporting polypeptide 1a4 is responsible for the hepatic uptake of cardiac glycosides in mice. Drug metabolism and disposition: the biological fate of chemicals 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29348124
  14. Ramos-Fransi A, Martinez-Pineiro A, Almendrote M et al. Myotilinopathy unmasked by statin treatment: A case report. Muscle Nerve 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29350769
  15. Parikh P, Tavee J, Soltanzadeh P et al. Anti-HMGCR autoantibody positive necrotizing autoimmune myopathy with dermatomyositis-like eruption. Muscle Nerve 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29346706
  16. Krysiak R, Szkrobka W, Okopien B. Moderate-dose simvastatin therapy potentiates the effect of vitamin D on thyroid autoimmunity in levothyroxine-treated women with Hashimoto's thyroiditis and vitamin D insufficiency. Pharmacological reports : PR 2017; 70:93-97. http://www.ncbi.nlm.nih.gov/pubmed/?term=29331793
  17. Klose G. [Statin-associated muscle symptoms]. MMW Fortschritte der Medizin 2018; 160:40-43. http://www.ncbi.nlm.nih.gov/pubmed/?term=29335944
  18. Karahalil B, Hare E, Koc G et al. Hepatotoxicity associated with statins. Arhiv za higijenu rada i toksikologiju 2017; 68:254-260. http://www.ncbi.nlm.nih.gov/pubmed/?term=29337684
  19. Deljehier T, Pariente A, Miremont-Salame G et al. Rhabdomyolysis after co-administration of a statin and fusidic acid: an analysis of the literature and of the WHO database of adverse drug reactions. Br J Clin Pharmacol 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29337401
  20. Alzahrani T, Liappis AP, Baddour LM, Karasik PE. Statin use and the risk of cardiovascular implantable electronic device infection: A cohort study in a veteran population. Pacing and clinical electrophysiology : PACE 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29341172
  21. Toth PP, Patti AM, Giglio RV et al. Management of Statin Intolerance in 2018: Still More Questions Than Answers. Am J Cardiovasc Drugs 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29318532
  22. Tan JT, Barry AR. Coenzyme Q10 for statin-associated myalgia. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 2018; 75:15. http://www.ncbi.nlm.nih.gov/pubmed/?term=29317393
  23. Ruisinger JF, Moriarty PM, Backes JM. Coenzyme Q10 for statin-associated myalgia. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 2018; 75:14-15. http://www.ncbi.nlm.nih.gov/pubmed/?term=29317392
  24. Rebalka IA, Cao AW, Raleigh MJ et al. Statin Therapy Negatively Impacts Skeletal Muscle Regeneration and Cutaneous Wound Repair in Type 1 Diabetic Mice. Front Physiol 2017; 8:1088. http://www.ncbi.nlm.nih.gov/pubmed/?term=29311999
  25. Wooten JM. A Brief Drug Class Review: Considerations for Statin Use, Toxicity, and Drug Interactions. Southern medical journal 2018; 111:39-44. http://www.ncbi.nlm.nih.gov/pubmed/?term=29298368
  26. Jiang S, Venners SA, Li K et al. Effect modification by region in the associations of LEP G2548A and LEPR Q223R polymorphisms with statin-induced CK elevation. Oncotarget 2017; 8:107565-107576. http://www.ncbi.nlm.nih.gov/pubmed/?term=29296187

Stroke and CNS

  1. Singh D, Lippmann S. Can Statins Diminish Depression? The primary care companion for CNS disorders 2018; 20. http://www.ncbi.nlm.nih.gov/pubmed/?term=29372939
  2. Zhao L, Xiao Y, Xiu J et al. Protection against the Neurotoxic Effects of beta-Amyloid Peptide on Cultured Neuronal Cells by Lovastatin Involves Elevated Expression of alpha7 Nicotinic Acetylcholine Receptors and Activating Phosphorylation of Protein Kinases. The American journal of pathology 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29341888
  3. Dai YY, Huang ZX, Liu XT, Wang QZ. [Risk factors for recurrence of large atherosclerotic cerebral infarction]. Nan fang yi ke da xue xue bao = Journal of Southern Medical University 2017; 37:1678-1682. http://www.ncbi.nlm.nih.gov/pubmed/?term=29292265

Triglycerides/HDL

  1. Vladimirov S, Gojkovic T, Spasojevic-Kalimanovska V et al. Influence of LCAT and CETP activity on the reverse cholesterol transport and modification of HDL particles in statin-treated coronary artery disease patients and healthy subjects. Atherosclerosis 2017; 263:e217. http://www.ncbi.nlm.nih.gov/pubmed/?term=29365842
  2. Reyes-Soffer G, Khavani M, Holleran S et al. Lipidomic and proteomic predictors of drastic reductions of HDL in the accord lipid trial. Atherosclerosis 2017; 263:e96. http://www.ncbi.nlm.nih.gov/pubmed/?term=29366287
  3. Ong KL, Waters DD, Fayyad R et al. Relationship of High-Density Lipoprotein Cholesterol With Renal Function in Patients Treated With Atorvastatin. J Am Heart Assoc 2018; 7. http://www.ncbi.nlm.nih.gov/pubmed/?term=29358194
  4. Nicholls SJ, Puri R, Ballantyne CM et al. MILANO-PILOT: will infusing HDL mimetics containing apoA-imilano continue to regress coronary atherosclerosis in the modern era of intensive statin therapy? Atherosclerosis 2017; 263:e11. http://www.ncbi.nlm.nih.gov/pubmed/?term=29365456
  5. Morieri ML, Shah HS, Lovato L et al. Increase in apoliporotein-A2 Levels is associated with lower cardiovascular risk in the accord lipid trial. Atherosclerosis 2017; 263:e43. http://www.ncbi.nlm.nih.gov/pubmed/?term=29366108
  6. Hoeke G, Wang Y, Van Dam A et al. Statin treatment potentiates the lipid-lowering and anti-atherogenic effect of bat activation by accelerating lipoprotein remnant clearance. Atherosclerosis 2017; 263:e212. http://www.ncbi.nlm.nih.gov/pubmed/?term=29365823
  7. Gojkovic T, Vladimirov S, Spasojevic-Kalimanovska V et al. Association of LDL phenotypes with cholesterol synthesis and HDL subclasses in statin-treated coronary artery disease patients and healthy subjects. Atherosclerosis 2017; 263:e205. http://www.ncbi.nlm.nih.gov/pubmed/?term=29365796
  8. Budoff M, Brent Muhlestein J, Le VT et al. Effect of Vascepa (icosapent ethyl) on progression of coronary atherosclerosis in patients with elevated triglycerides (200-499 mg/dL) on statin therapy: Rationale and design of the EVAPORATE study. Clin Cardiol 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29365351

Trials

  1. Simes J, Robledo KP, White HD et al. D-dimer Predicts Long-Term Cause-Specific Mortality, Cardiovascular Events and Cancer in Stable Coronary Heart Disease Patients: The LIPID Study. Circulation 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29367425
  2. Putzu A, Ferrari E, Gallo M et al. Randomized Evidence on Perioperative Statin Therapy in Cardiac Surgery. The Annals of thoracic surgery 2018; 105:665-666. http://www.ncbi.nlm.nih.gov/pubmed/?term=29362180
  3. Pechlivanis S, Moebus S, Lehmann N et al. Pharmacogenetic association of blood-lipid related genetic variants with 5-year progression of coronary artery calcification following the treatment with statin in the Heinz Nixdorf Recall study. Atherosclerosis 2017; 263:e278. http://www.ncbi.nlm.nih.gov/pubmed/?term=29366052
  4. Nicholls SJ, Puri R, Ballantyne CM et al. MILANO-PILOT: will infusing HDL mimetics containing apoA-imilano continue to regress coronary atherosclerosis in the modern era of intensive statin therapy? Atherosclerosis 2017; 263:e11. http://www.ncbi.nlm.nih.gov/pubmed/?term=29365456
  5. Huesch MD. Association of Baseline Statin Use Among Older Adults Without Clinical Cardiovascular Disease in the SPRINT Trial. JAMA Intern Med 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29356825
  6. Greve AM, Bang CN, Boman K et al. Effect Modifications of Lipid-Lowering Therapy on Progression of Aortic Stenosis (from the Simvastatin and Ezetimibe in Aortic Stenosis [SEAS] Study). Am J Cardiol 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29361285
  7. Budoff M, Brent Muhlestein J, Le VT et al. Effect of Vascepa (icosapent ethyl) on progression of coronary atherosclerosis in patients with elevated triglycerides (200-499 mg/dL) on statin therapy: Rationale and design of the EVAPORATE study. Clin Cardiol 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29365351
  8. Seo YH, Seo DJ, Song IG et al. Rationale of decreasing low-density lipoprotein cholesterol below 70 mg/dL in patients with coronary artery disease: A retrospective virtual histology. Intravascular ultrasound study. Cardiology journal 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29341060
  9. Ozbicer S, Gur M, Kalkan G et al. Chronic statin treatment is a predictor of pre-interventional infarct related artery patency in patients with ST elevation myocardial infarction treated with percutaneous coronary intervention. Kardiol Pol 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29350388
  10. Mayyas F, Baydoun D, Ibdah R, Ibrahim K. Atorvastatin Reduces Plasma Inflammatory and Oxidant Biomarkers in Patients With Risk of Atherosclerotic Cardiovascular Disease. Journal of cardiovascular pharmacology and therapeutics 2018:1074248417753677. http://www.ncbi.nlm.nih.gov/pubmed/?term=29343081
  11. Krysiak R, Szkrobka W, Okopien B. Moderate-dose simvastatin therapy potentiates the effect of vitamin D on thyroid autoimmunity in levothyroxine-treated women with Hashimoto's thyroiditis and vitamin D insufficiency. Pharmacological reports : PR 2017; 70:93-97. http://www.ncbi.nlm.nih.gov/pubmed/?term=29331793
  12. Acampa M, Lazzerini PE, Guideri F et al. Previous use of statins and atrial electrical remodeling in patients with cryptogenic stroke. Cardiovascular & hematological disorders drug targets 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29332603
  13. Tsujimoto T, Kajio H. Favorable effects of statins in the treatment of heart failure with preserved ejection fraction in patients without ischemic heart disease. Int J Cardiol 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29307549
  14. Chen IC, Tseng WK, Li YH et al. Effect of cilostazol on plasma levels of proprotein convertase subtilisin/kexin type 9. Oncotarget 2017; 8:108042-108053. http://www.ncbi.nlm.nih.gov/pubmed/?term=29296222
  15. Canepa M, Artom N, Ameri P et al. Short-term effect of rosuvastatin treatment on arterial stiffness in individuals with newly-diagnosed heterozygous familial hypercholesterolemia. Int J Cardiol 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=29290422

Women and elderly

  1. Ozerova I, Metelskaya V, Gavrilova N. Changes in subfractional distribution of apolipoprotein B-containing lipoproteins in patients with coronary atherosclerosis on statin therapy: Gender differences. Atherosclerosis 2017; 263:e190. http://www.ncbi.nlm.nih.gov/pubmed/?term=29365737
  2. Ofori-Asenso R, Jakhu A, Curtis AJ et al. A Systematic Review and Meta-analysis of the Factors Associated With Nonadherence and Discontinuation of Statins Among People Aged >/=65 Years. J Gerontol A Biol Sci Med Sci 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29360935
  3. Huesch MD. Association of Baseline Statin Use Among Older Adults Without Clinical Cardiovascular Disease in the SPRINT Trial. JAMA Intern Med 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29356825
  4. Esteve-Valverde E, Ferrer-Oliveras R, Gil-Aliberas N et al. Pravastatin for Preventing and Treating Preeclampsia: A Systematic Review. Obstetrical & gynecological survey 2018; 73:40-55. http://www.ncbi.nlm.nih.gov/pubmed/?term=29368790
  5. Ruscica M, Macchi C, Pavanello C et al. Appropriateness of statin prescription in the elderly. Eur J Intern Med 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29310996
  6. Mortensen MB, Falk E. Primary Prevention With Statins in the Elderly. J Am Coll Cardiol 2018; 71:85-94. http://www.ncbi.nlm.nih.gov/pubmed/?term=29301631
 
 
Twitter
IAS Website
For information
You are now on the editors mailing list of the IAS Statin Newsletter.
The IAS Statin Newsletter is part of the IAS News and Literature update service.
 
This activity is supported by an educational grant from Pfizer.